Targeted prostate cancer trial for hispanic and black men withdrawn before start

NCT ID NCT06392841

Terminated Disease control Sponsor: Qian Qin Source: ClinicalTrials.gov ↗

Summary

This study aimed to test a combination of two drugs, niraparib and abiraterone, plus a steroid, in men with newly diagnosed, advanced prostate cancer that had spread and had specific genetic changes. It specifically sought Hispanic/Latino and non-Hispanic Black participants to see how well the treatment lowered prostate-specific antigen (PSA) levels. The study was withdrawn before any participants were enrolled.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

Explore the condition pages connected to this study.

BRCA1 GENE MUTATION BRCA2 GENE MUTATION BRIP1 GENE MUTATION CHEK2 GENE MUTATION DELETERIOUS HRR GENE MUTATION FANCA GENE MUTATION METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) PALB2 GENE MUTATION RAD51B GENE MUTATION RAD54L GENE MUTATION